Immunotherapy has been the buzzword for cancer treatment over the last few years. With long impending clinical trials and research activities carried out using chimeric antigen receptor cells (CAR-T) cells, major players in the pharmaceuticals industry are expected to launch various products in 2017 and commercialize the product in the following two to three years. The idea behind introducing CAR-T cells is to specifically target and attack cancer cells and thereby, achieve higher treatment success rate. It involves adoptive cell transfer: extraction, expansion and modification of patient’s T-cell and then transferring back to patient’s body system. Sales of CAR-T-cell therapy product is expected to increase at double-digit growth rate, with major players in the organized sector expected to account for major share of the market.
To know the latest trends and insights of this market, click the link below:
Car-T Cell Therapy Market Dynamics
Once commercially released, it will be a lifesaving therapy for millions of people creating major opportunities for players in the Car-T cell therapy market. Moreover, it is expected to help in treatment of children diagnosed with acute lymphoblastic leukemia (ALL) in B cells. Introduction of the drug is expected to be especially beneficial for leukemia patients. According to the U.S. National Cancer Institute, over 339,000 people in the U.S., suffered from leukemia in 2012, with an estimated 1.5% of the population in the country expected to be detect with leukemia once in their lifetime. Growing prevalence rate and increasing demand for effective treatment modalities is expected to create new opportunities for market players.
The Car-T cell therapy market is expected to be highly consolidated over the next few years, with the three major players accounting for major share of market revenue. The benefits of the launch of this drug is expected to benefit manufacturers, pharmacies and hospitals, and patients across value chain alike.
Though the market is expected to gain significant traction over the forecast period, failing clinical trials, low success rate towards solid tumors, and cost structure in scaling up personalized medicines towards high cost to return profits are major challenges faced by the companies. CAR-T cell personalized treatment cell might require change in capacity of bioreactors of around 5 thousand liters. Moreover, it will require companies to train staff, incurring additional cost during the initial phase. Production is expected to increase significantly by 2020.
Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/102
Car-T Cell Therapy Market – Regional Analysis
North America and Europe are expected to dominate the overall CAR-T cells market throughout the forecast period. The regions are early adopters of newly-developed technologies. Moreover, demand is expected to be further propelled by large consumer base in these regions. As per estimates, North America spends an average of over 10% of the gross income on healthcare, with the large geriatric population in the region being the largest spenders. With over 80% of personalized medicine market captured by North America and Europe, the CAR-T Cell therapy is expected to achieve significant sales in these regions. Moreover, increasing popularity of personalized medicines would further propel demand for CAR T cell products in these regions.
Asia Pacific is projected to emerge as a lucrative market for companies engaged in CAR-T cell therapy, although commercialization is expected only towards the latter part of the forecast period. Market in Asia Pacific is expected to grow at relatively sluggish rate between 2017 and 2022. Japan is projected to be the key market in Asia Pacific for the players. However, low consumer base and low prevalence rate of cancer compared to developed region would lead to moderate growth opportunities in near future.
Request for Report Customization: https://www.coherentmarketinsights.com/insight/request-customization/102
Car-T Cell Therapy Market – Competitor Analysis
Juno Therapeutics, Kite, and Novartis are currently engaged in CAR-T cell therapeutic products – commercialization of same is expected to commence in 2017.
Kite is awaiting FDA-approval for its KTE-C19, with clinical trials being conducted at the National Cancer Institute. Judo’s JCAR015 is in phase II for ALL, while Novartis sees market opportunity with CAR-T Cell therapy, CTL019. With high remission rates, the product is expected to create exponential opportunities for the players in the Car-T cell therapy market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Company Name: Coherent Market Insights
Contact Person: Raj Shah
Address:1001 4th Ave #3200
Country: United States